TransCode Therapeutics
(NASDAQ) RNAZ
TransCode Therapeutics Financials at a Glance
Market Cap
$8.54M
Revenue (TTM)
$0.00
Net Income (TTM)
$27.13M
EPS (TTM)
$-242.08
P/E Ratio
-0.04
Dividend
$0.00
Beta (Volatility)
0.00 (Low)
Dividend
$0.00
Beta (Volatility)
0.00 (Low)
Price
$8.92
Volume
427
Open
$8.80
Price
$8.92
Volume
427
Open
$8.80
Previous Close
$8.92
Daily Range
$8.74 - $8.92
52-Week Range
$6.08 - $46.76
Dividend
$0.00
Beta (Volatility)
0.00 (Low)
Price
$8.92
Volume
427
Open
$8.80
Previous Close
$8.92
Daily Range
$8.74 - $8.92
52-Week Range
$6.08 - $46.76
RNAZ News
RNAZ: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout TransCode Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
7
CEO
Thomas A. Fitzgerald, MBA
Headquarters
Boston, MA 02109, US
RNAZ Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-1763%
Return on Capital
-8%
Return on Assets
-5%
Earnings Yield
-25.00%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$8.54M
Shares Outstanding
917.00K
Volume
427
Short Interest
0.00%
Avg. Volume
259.87K
Financials (TTM)
Gross Profit
$534.86K
Operating Income
$15.66M
EBITDA
$16.19M
Operating Cash Flow
$13.34M
Capital Expenditure
$21.76K
Free Cash Flow
$13.36M
Cash & ST Invst.
$5.81M
Total Debt
$38.29K
TransCode Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$4.78K
+96.3%
Gross Margin
0.00%
N/A
Market Cap
$8.54M
N/A
Market Cap/Employee
$1.22M
N/A
Employees
7
N/A
Net Income
$4.86M
-109.2%
EBITDA
$4.85M
-121.9%
Quarterly Fundamentals
Net Cash
$2.84M
+64.6%
Accounts Receivable
$198.30K
+1559.0%
Inventory
$0.00
N/A
Long Term Debt
$0.00
N/A
Short Term Debt
$0.00
-100.0%
Return on Assets
-5.19%
N/A
Return on Invested Capital
-7.55%
N/A
Free Cash Flow
$4.08M
-4.0%
Operating Cash Flow
$4.08M
-4.4%